<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02065401</url>
  </required_header>
  <id_info>
    <org_study_id>SPD602-112</org_study_id>
    <nct_id>NCT02065401</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt)</brief_title>
  <official_title>A Phase 1, Open-label, Randomized, 3-Period, Relative Bioavailability Study Comparing the Pharmacokinetics of Granule and Tablet Formulations of Deferitazole (Disodium Salt) and a Capsule Formulation of Deferitazole (Magnesium Hydroxide Salt), Each Administered as a Single Oral Dose</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shire</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Takeda</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the pharmacokinetic profiles of deferitazole after&#xD;
      administration of granule and tablet formulations of a deferitazole disodium salt to a&#xD;
      capsule formulation of deferitazole magnesium hydroxide salt (reference formulation) in&#xD;
      healthy adult subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <why_stopped>
    This study was withdrawn until the evaluation of the nonclinical rat findings is complete.&#xD;
  </why_stopped>
  <start_date type="Anticipated">February 28, 2014</start_date>
  <completion_date type="Anticipated">March 19, 2014</completion_date>
  <primary_completion_date type="Anticipated">March 19, 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve (AUC) of Deferitazole</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
    <description>AUC of disodium salt granule, disodium salt tablet, and magnesium hydroxide salt</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) of Deferitazole</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
    <description>Cmax of disodium salt granule, disodium salt tablet, and magnesium hydroxide salt</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Taste of Deferitazole</measure>
    <time_frame>Immediately after dose and 5 minutes post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bioequivalence of Deferitazole Disodium Salt Granule Formulation With Tablet Formulation</measure>
    <time_frame>Up to 120 hours post-dose</time_frame>
    <description>Compare the pharmacokinetic profile of granule formulation with pharmacokinetic profile of tablet formulation</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Deferitazole (disodium salt, granule)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferitazole (disodium salt, tablet)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Deferitazole (magnesium hydroxide salt)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferitazole (disodium salt, granule)</intervention_name>
    <description>Single oral dose of 1500 mg administered on Day 1</description>
    <arm_group_label>Deferitazole (disodium salt, granule)</arm_group_label>
    <other_name>SPD602, SSP-004184, SSP-004184SS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferitazole (disodium salt, tablet)</intervention_name>
    <description>Single oral dose of 1500 mg administered on Day 1</description>
    <arm_group_label>Deferitazole (disodium salt, tablet)</arm_group_label>
    <other_name>SPD602, SSP-004184, SSP-004184SS</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Deferitazole (magnesium hydroxide salt)</intervention_name>
    <description>Single oral dose of 2400 mg administered on Day 1</description>
    <arm_group_label>Deferitazole (magnesium hydroxide salt)</arm_group_label>
    <other_name>SPD602, SSP-004184AQ, SSP-004184</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age 18-65 years inclusive at the time of consent.&#xD;
&#xD;
          2. Must be considered &quot;healthy&quot;.&#xD;
&#xD;
          3. Serum ferritin, hemoglobin and erythrocyte indices (packed cell volume, mean&#xD;
             corpuscular volume and mean corpuscular hemoglobin concentration) within normal range.&#xD;
&#xD;
          4. Willingness to comply with any applicable contraceptive requirements of the protocol&#xD;
             and is:&#xD;
&#xD;
               -  Male, or&#xD;
&#xD;
               -  Female of non-childbearing potential (defined as a female who is post-menopausal&#xD;
                  )&#xD;
&#xD;
               -  Non-pregnant, non-lactating female&#xD;
&#xD;
               -  Females must be at least 90 days post partum or nulliparous.&#xD;
&#xD;
          5. Body weight equal to or greater than 60kg.&#xD;
&#xD;
          6. Ability to swallow a dose of the investigational product.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Subject has a clinically significant history or a disorder detected during the medical&#xD;
             interview/physical examination.&#xD;
&#xD;
          2. Acute illness.&#xD;
&#xD;
          3. Oral condition:&#xD;
&#xD;
               -  Has history of oral surgery (including extractions) within 4 weeks, operative&#xD;
                  dental work within 7 days, or a presence of any clinically significant oral&#xD;
                  pathology (as determined by the investigator) including lesions, sores or&#xD;
                  inflammation which would interfere with assessments.&#xD;
&#xD;
               -  Has fixed retainers, orthodontic appliances, or either maxillary and/or&#xD;
                  mandibular dentures or other appliances which may interfere with swilling or&#xD;
                  tasting the formulations.&#xD;
&#xD;
               -  Has current or recurrent disease that could affect the mouth and interfere with&#xD;
                  the taste assessment.&#xD;
&#xD;
               -  Has severe gingivitis, periodontitis or rampant caries.&#xD;
&#xD;
               -  Has the presence of oral or peri-oral ulceration including herpetic lesions&#xD;
&#xD;
               -  Has elective dentistry scheduled during the study duration.&#xD;
&#xD;
          4. Subject has a history of thyroid disorder that has not been stabilized on thyroid&#xD;
             medication or treatment.&#xD;
&#xD;
          5. History of alcohol or other substance abuse within the year.&#xD;
&#xD;
          6. A positive screen for alcohol or drugs of abuse.&#xD;
&#xD;
          7. Confirmed systolic blood pressure &gt;139mmHg or &lt;89mmHg, and diastolic blood pressure&#xD;
             &gt;89mmHg or&lt;49mmHg.&#xD;
&#xD;
          8. Routine consumption of more than 2 units of caffeine per day or subjects who&#xD;
             experience caffeine withdrawal headaches.&#xD;
&#xD;
          9. Male subjects who consume more than 3 units of alcohol per day. Female subjects who&#xD;
             consume more than 2 units of alcohol per day.&#xD;
&#xD;
         10. A positive human immunodeficiency virus antibody screen, hepatitis B surface antigen,&#xD;
             or hepatitis C virus antibody.&#xD;
&#xD;
         11. Current use of any other medication (including over-the-counter, herbal, or&#xD;
             homeopathic preparations)&#xD;
&#xD;
         12. Current use of iron supplements and/or multivitamins.&#xD;
&#xD;
         13. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing&#xD;
             products.&#xD;
&#xD;
         14. Donation of blood or blood products (e.g., plasma or platelets) within 60 days.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Takeda</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Pharmacology of Miami</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>February 10, 2014</study_first_submitted>
  <study_first_submitted_qc>February 14, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2014</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Magnesium Hydroxide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

